May 7, 2025 12:58 PM EDTUpdated 01:19 PM

Avadel can pursue label expansion for narcolepsy drug Lumryz after court ruling

Alexis Kramer

Deputy Editor

Avadel Pharmaceuticals can try to expand the use of its blockbuster narcolepsy drug after a federal appeals court overturned an order that had barred it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avadel can pursue label expansion for narcolepsy drug Lumryz after court ruling

Alexis Kramer

Deputy Editor

Sign up to read this article for free.

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Avadel can pur­sue la­bel ex­pan­sion for nar­colep­sy drug Lum­ryz af­ter court rul­ing

Alexis Kramer

Deputy Editor

Sign up to read this article for free.

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Avadel can pursue label expansion for narcolepsy drug Lumryz after court ruling

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges